Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Trellus HealthFRA:85Q EV-to-EBITDA is 0.13 as of Sep. 02, 2026, which is 70% below its 10-year median of 0.44. The stock has 2 warning signs investors should review. Among 515 Healthcare Providers & Services companies, Trellus Health ranks better than 99.03% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Trellus Health's enterprise value is €-0.75 Mil.
Trellus Health's EBITDA for the trailing twelve months (TTM) ended in Jun. 2025 was €-5.61 Mil. Therefore, Trellus Health's EV-to-EBITDA for today is 0.13.
The historical rank and industry rank for Trellus Health's EV-to-EBITDA or its related term are showing as below:
FRA:85Q'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -0.13 Med: 0.44 Max: 0.57
Current: 0.14
During the past 5 years, the highest EV-to-EBITDA of Trellus Health was 0.57. The lowest was -0.13. And the median was 0.44.
FRA:85Q's EV-to-EBITDA is ranked better than 99.03% of 515
companies
in the Healthcare Providers & Services industry
Industry Median: 10.43
vs FRA:85Q: 0.14
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Trellus Health's PE Ratio (TTM) for today is calculated as:
Trellus Health's share price for today is €0.0005.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Trellus Health's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2025 was €-0.046.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Trellus Health's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:85Q vs VEEV, BTSG, TEM: EV-to-EBITDA Comparison
For the Health Information Services subindustry, Trellus Health's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Trellus Health EV-to-EBITDA vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Trellus Health's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Trellus Health's EV-to-EBITDA falls into.
Trellus Health's current Enterprise Value is €-0.75 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Trellus Health's EBITDA for the trailing twelve months (TTM) ended in Jun. 2025 was €-5.61 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Trellus Health (FRA:85Q) has a EV-to-EBITDA of 0.13 as of Sep. 02, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Trellus Health. This is 70% below median its historical median of 0.44. According to the industry distribution chart, Trellus Health ranks #5 out of 515 companies in the Healthcare Providers & Services industry, placing it in the top 1%.
Is Trellus Health's EV-to-EBITDA too high?
Trellus Health's current EV-to-EBITDA of 0.13 is 70% below median its 10-year median of 0.44. The Healthcare Providers & Services industry median EV-to-EBITDA is 10.43. Trellus Health's value of 0.13 is 98.8% below this industry median. Based on the distribution chart, Trellus Health ranks #5 out of 515 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers.
How does Trellus Health's EV-to-EBITDA compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, Trellus Health ranks #5 out of 515 companies for EV-to-EBITDA. This places Trellus Health in the top 1% of its industry — outperforming the majority of peers. The industry median EV-to-EBITDA is 10.43. Trellus Health's value of 0.13 is 98.8% below this benchmark. While the company's 10-year median is 0.44 vs. the industry median of 10.43, Trellus Health has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Healthcare Providers & Services company?
The median EV-to-EBITDA among Healthcare Providers & Services companies is 10.43, based on 515 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Trellus Health's current EV-to-EBITDA of 0.13 is 98.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Trellus Health. For the Healthcare Providers & Services industry, the median EV-to-EBITDA is 10.43 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Trellus Health's current EV-to-EBITDA is 0.13, which is 70% below median its own 10-year median of 0.44. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Trellus Health stock overvalued right now?
Trellus Health (FRA:85Q) has a current EV-to-EBITDA of 0.13. The current EV-to-EBITDA is 0.13, which is 70% below median its 10-year median of 0.44 and 98.8% below the Healthcare Providers & Services industry median of 10.43. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Trellus Health (FRA:85Q), the current EV-to-EBITDA is 0.13 as of Sep. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Trellus Health PLC is commercializing the provision of digital chronic condition management solutions for employers and health plans that utilize the scientifically validated GRITT resilience-based methodology and a proprietary HIPAA-compliant technology platform called TrellusElevate to coordinate and deliver personalized care. The company is initially focused on Inflammatory Bowel Diseases, which include the chronic incurable conditions of Crohn's Disease and ulcerative colitis but considers its approach to have potential utility and demand across many chronic conditions.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:85Q has been successfully added to your 
